However, some studies have found that for low-risk patients such as Core-binding factor acute myeloid leukemia (CBF-AML), the efficacy of ASCT is superior to that of allo-HSCT (Al Hamed et al., 2024). This evidence concerns the gene CEBPZ and acute myeloid leukemia.